HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Salmons, N. Articles by Tanière, P. Search for Related Content PubMed PubMed Citation Articles by Salmons, N. Articles by Tanière, P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB IMATINIB MESYLATE

Lymphomatoid granulomatosis in a patient previously diagnosed with a gastrointestinal stromal tumour and treated with imatinib

University Hospital of Birmingham Foundation Trust and University of Birmingham, Edgbaston, Birmingham, UK

Correspondence to:
Dr P Tanière
Department of Cellular Pathology, University Hospital of Birmingham, Birmingham B15 2TT, UK; phillipe.taniere@uhb.nhs.uk 22 February 2006

Abbreviations: EBV, Epstein–Barr virus; GIST, gastrointestinal stromal tumour; LYG, lymphomatoid granulomatosis

The first 150 words of the full text of this article appear below.

A 39-year-old man with a history of recurrent malignant gastrointestinal stromal tumour (GIST) of the small bowel, treated with imatinib, presented with a 2-week history of shortness of breath, fluctuating fever, pancytopenia and bilateral airspace opacities. He was treated for pneumonia, but his condition deteriorated and he died 6 weeks after admission. We present the subsequent postmortem examination findings.

CLINICAL HISTORY
This is the case of a 39-year-old man, with a medical history of malignant gastrointestinal stromal tumour (GIST) of the small bowel, resected 2.5 years before this episode. Local recurrence and liver metastases occurred 18 months from initial diagnosis. Imatinib mesylate 400 mg once daily (Glivec; Novartis, Basel, Switzerland) was started, with a good clinical response (including a reduction in tumour size). Family history included a sister diagnosed with cancer and mother with a brain tumour (unfortunately, further information could not be obtained).

The patient was admitted in September 2004 with . . . [Full text of this article]